6104-41-2

Basic information

• Product Name: Pyrimidine, 4-methoxy- (6CI,7CI,8CI,9CI)
• Synonyms: Pyrimidine, 4-methoxy- (6CI,7CI,8CI,9CI);4-Methoxypyrimidine;Methyl 4-pyrimidinyl ether
• CAS NO: 6104-41-2
• Molecular Formula: C₅H₆N₂O
• Molecular Weight: 110.12
• Product Categories: PYRIMIDINE
• Mol File: 6104-41-2.mol

Chemical Properties

• Boiling Point: 70°C/22mmHg(lit.)
• Flash Point: 64.4 °C
• Appearance: /
• Density: 1.102g/cm³
• Vapor Pressure: 1.15mmHg at 25°C
• Refractive Index: 1.4990-1.5030
• CAS DataBase Reference: Pyrimidine, 4-methoxy- (6CI,7CI,8CI,9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: Pyrimidine, 4-methoxy- (6CI,7CI,8CI,9CI)(6104-41-2)
• EPA Substance Registry System: Pyrimidine, 4-methoxy- (6CI,7CI,8CI,9CI)(6104-41-2)

Safety Data

• Hazardous Substances Data: 6104-41-2(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
Pyrimidine, 4-methoxy(6CI,7CI,8CI,9CI) is used as a potential pharmaceutical candidate for the development of new drugs. Its unique structure and properties may offer advantages over existing pyrimidine-based drugs, such as improved efficacy, selectivity, or reduced side effects.
Used in Biochemical Research:
Pyrimidine, 4-methoxy(6CI,7CI,8CI,9CI) is used as a research tool in biochemical studies. Its unique structure and potential reactivity may provide insights into the mechanisms of pyrimidine-based biomolecules and their interactions with other cellular components.
Used in Drug Synthesis:
Pyrimidine, 4-methoxy(6CI,7CI,8CI,9CI) can be used as a building block or intermediate in the synthesis of more complex pyrimidine-based compounds. Its unique properties may enable the development of novel drugs with improved pharmacological profiles.
Used in Drug Delivery Systems:
Pyrimidine, 4-methoxy(6CI,7CI,8CI,9CI) can be incorporated into drug delivery systems to improve the bioavailability, targeting, and therapeutic efficacy of pyrimidine-based drugs. Its unique structure may allow for the development of innovative drug delivery platforms, such as nanoparticles or liposomes, that can enhance the performance of these compounds in vivo.

InChI:InChI=1/C5H6N2O/c1-8-5-2-3-6-4-7-5/h2-4H,1H3

Upstream product

• 186581-53-3 diazomethane 
• 51953-18-5 pyrimidine-4(3H)-one 
• 26452-81-3 4-chloro-6-methoxy-pyrimidine 
• 16285-69-1 3-(formylamino)-2-thiophenecarboxylic acid methyl ester 
• 43212-41-5 2,4-dichloro-6-methoxypyrimidine 
• 22536-63-6 2-chloro-4-methoxypyrimidine 
• 57054-92-9 5-bromo-2-chloro-4-methoxypyrimidine 
• 108782-92-9 4-O-(2-nitrophenyl)uridine 

Downstream Products

• 344353-70-4 (4-methoxypyrimidin-2-yl)methanol 
• 130532-95-5 α-(4-pyrimidyl)phenylacetonitrile 
• 17758-55-3 4-Methoxypyrimidine 1-oxide 
• 155-90-8 4-methoxypyrimidin-2-amine 
• 69543-97-1 4-bromo-6-methoxypyrimidine 
• 22930-71-8 pyrimidin-4-ylhydrazine 
• 6104-45-6 3-methylpyrimidin-4-one 
• 857042-18-3 5-[(hydroxyimino)(phenyl)methyl]-4-methoxypyrimidin-2(1H)-one 
• 18002-25-0 4-methoxy-2-pyrimidone 

Relevant articles and documents

Electron-deficient heteroarenium salts: An organocatalytic tool for activation of hydrogen peroxide in oxidations

A series of monosubstituted pyrimidinium and pyrazinium triflates and 3,5-disubstituted pyridinium triflates were prepared and tested as simple catalysts of oxidations with hydrogen peroxide, using sulfoxidation as a model reaction. Their catalytic efficiency strongly depends on the type of substituent and is remarkable for derivatives with an electron-withdrawing group, showing reactivity comparable to that of flavinium salts which are the prominent organocatalysts for oxygenations. Because of their high stability and good accessibility, 4-(trifluoromethyl)pyrimidinium and 3,5-dinitropyridinium triflates are the catalysts of choice and were shown to catalyze oxidation of aliphatic and aromatic sulfides to sulfoxides, giving quantitative conversions, high preparative yields and excellent chemoselectivity. The high efficiency of electron-poor heteroarenium salts is rationalized by their ability to readily form adducts with nucleophiles, as documented by low pKR+ values (pKR+ red > -0.5 V). Hydrogen peroxide adducts formed in situ during catalytic oxidation act as substrate oxidizing agents. The Gibbs free energies of oxygen transfer from these heterocyclic hydroperoxides to thioanisole, obtained by calculations at the B3LYP/6-311++g(d,p) level, showed that they are much stronger oxidizing agents than alkyl hydroperoxides and in some cases are almost comparable to derivatives of flavin hydroperoxide acting as oxidizing agents in monooxygenases.

Compounds and Uses Thereof - 848

This invention relates to novel compounds having the structural formula I below: and their pharmaceutically acceptable salts, tautomers or in vivo-hydrolysable precursors, compositions and methods of use thereof, wherein R1, R2, Rsu

Thienopyrimidine-based inhibitors of the Src family

Various thienopyrimidine-based analog compounds that selectively inhibit the Src family of tyrosine kinases. These compounds are thienopyrimidines and contain a hydrozone bridge created by heating a thienopyrimidine hydrazine with an aldehyde in ethanol at reflux. Such compounds are useful in the treatment of various diseases including hyperproliferative diseases, hematologic diseases, osteoporosis, neurological diseases, autoimmune diseases, allergic/immunological diseases, or viral infections.

SITE-SPECIFIC MODIFICATION OF THE PYRIMIDINE RESIDUE DURING THE DEPROTECTION OF THE FULLY-PROTECTED DIURIDYLIC ACID.

A study of four different O-4 and N-3 protected uridine derivatives, 4 to 7, for their stabilities under different conditions versus their abilities to undergo nucleophilic substitution reaction at C-4 by an appropriate oxygen or a nitrogen nucleophile has established a general strategy for the site-specific modification of a particular pyrimidine residue in a model fully protected diuridylic acid to give either UpC, CpC or UpU, depending upon the deprotection condition.